崔阳;张晓;
CUI Yang;ZHANG Xiao;Department of Rheumatology and Immunology, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences;

• 1:广东省人民医院(广东省医学科学院)风湿免疫科

摘要(Abstract)：

系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种育龄期,尤其是20～40岁女性高发的疾病。此年龄段患者多有怀孕生子的需求,但SLE患者合并妊娠时不但疾病本身可能反复或加重,不良妊娠风险亦显著增加,因此做好SLE患者妊娠期综合管理极其重要。本文主要阐述SLE与妊娠的相互影响及妊娠期SLE患者的综合管理,以期指导临床更好地认识该问题,从而改善SLE患者的妊娠结局。
Systemic lupus erythematosus(SLE) is a disease with a high incidence in women of childbearing age, especially 20-40 years old. Most patients at this age will have the need for pregnancy. However, when SLE combines with pregnancy, pregnant women are facing not only the risk of relapse and aggravation of lupus, but also the increased risk of adverse pregnancies. Therefore, it is very important to do well in the comprehensive management of pregnancy in SLE patients. This paper focused on the interaction between SLE and pregnancy, as well as the management of SLE in pregnant patients, aiming to better understand and improve the pregnancy outcome of SLE patients.

关键词(KeyWords)： 系统性红斑狼疮;妊娠管理;孕妇;胎儿
systemic lupus erythematosus;pregnancy management;pregnant women;fetus

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 崔阳;张晓;
CUI Yang;ZHANG Xiao;Department of Rheumatology and Immunology, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences;

参考文献(References)：

• [1] Park MC,Park YB,Jung SY,et al.Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy[J].Lupus,2004,13:569- 574.
• [2] Jakobsen IM,Helmig RB,Stengaard-Pedersen K.Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients:an incident cohort from a stable referral population followed during 1990-2010[J].Scand J Rheumatol,2015,44:377- 384.
• [3] Palma Dos Reis CR,Cardoso G,Carvalho C,et al.Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus[J].Clin Rev Allergy Immunol,2019.doi:10.1007/s12016- 019- 08762- 9.[Epub ahead of print].
• [4] Sammaritano LR.Management of Systemic Lupus Erythematosus During Pregnancy[J].Annu Rev Med,2017,68:271- 285.
• [5] Tedeschi SK,Massarotti E,Guan H,et al.Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy[J].Lupus,2015,24:1283- 1292.
• [6] Kattah AG,Garovic VD.Pregnancy and Lupus Nephritis[J].Semin Nephrol,2015,35:487- 499.
• [7] Cozzani E,Drosera M,Gasparini G,et al.Serology of Lupus Erythematosus:Correlation between Immunopathologi-cal Features and Clinical Aspects[J].Autoimmune Dis,2014,2014:321359.
• [8] Teng YKO,Bredewold EOW,Rabelink TJ,et al.An evidence-based approach to pre-pregnancy counselling for pa-tients with systemic lupus erythematosus[J].Rheumatology,2018,57:1707- 1720.
• [9] Brito-Zerón P,Izmirly PM,Ramos-Casals M,et al.The clinical spectrum of autoimmune congenital heart block[J].Nat Rev Rheumatol,2015,11:301- 312.
• [10] Kan N,Silverman ED,Kingdom J,et al.Serial echocardiography for immune-mediated heart disease in the fetus:results of a risk-based prospective surveillance strategy[J].Prenat Diagn,2017,37:375- 382.
• [11] Maynard S,Guerrier G,Duffy M.Pregnancy in Women With Systemic Lupus and Lupus Nephritis[J].Adv Chronic Kidney Dis,2019,26:330- 337.
• [12] Nahal SK,Selmi C,Gershwin ME.Safety issues and recommendations for successful pregnancy outcome in systemic lupus erythematosus[J].J Autoimmun,2018,93:16- 23.
• [13] Lazzaroni MG,Dall Ara F,Fredi M,et al.A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus[J].J Autoimmun,2016,74:106- 117.
• [14] Petri M.Pregnancy and Systemic Lupus Erythematosus[J].Best Pract Res Clin Obstet Gynaecol,2019,19:30133- 30136.
• [15] Espinosa G,Cervera R.Current treatment of antiphos-pholipid syndrome:lights and shadows[J].Nat Rev Rheumatol,2015,11:586- 596.
• [16] Hwang J,Shin S,Kim Y,et al.Epidemiology of Antiphospholipid Syndrome in Korea:a Nationwide Population-based Study[J].J Korean Med Sci,2020,35:e35.
• [17] Limper M,de Leeuw K,Lely AT,et al.Diagnosing and treating antiphospholipid syndrome:a consensus paper[J].Neth J Med,2019,77:98- 108.
• [18] Lazzaroni MG,Dall Ara F,Fredi M,et al.A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus[J].J Autoimmun,2016,74:106- 117.
• [19] Cavazzana I,Andreoli L,Limper M,et al.Update on Antiphospholipid Syndrome:Ten Topics in 2017[J].Curr Rheumatol Rep,2018,20:15.
• [20] Andreoli L,Fredi M,Nalli C,et al.Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome[J].J Autoimmun,2012,38:J197-J208.
• [21] Ruiz-Irastorza G,Crowther M,Branch W,et al.Antiphospholipid syndrome[J].Lancet,2010,376:1498- 1509.
• [22] Buyon JP,Kim MY,Guerra MM,et al.Predictors of Pregnancy Outcomes in Patients With Lupus[J].Ann Intern Med,2015,163:153.
• [23] Liu T,Gu J,Wan L,et al.“Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort[J].Arthritis Res Ther,2020,22:33.
• [24] Marchetti T,Ribi C,Perneger T,et al.Prevalence,persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus[J].Rheumatology,2018,57:1350- 1357.
• [25] Bertin D,Beziane A,Resseguier N,et al.Interest of IgG and IgM antiprothrombin autoantibodies in the exploration of antiphospholipid syndrome:a 5-year retrospective study[J].Rheumatology (Oxford),2019,pii:z453.
• [26] Tektonidou MG,Andreoli L,Limper M,et al.EULAR recommendations for the management of antiphospholipid syndrome in adults[J].Ann Rheum Dis,2019,78:1296- 1304.
• [27] 中国系统性红斑狼疮研究协作组专家组,国家风湿病数据中心.中国系统性红斑狼疮患者围产期管理建议[J].中华医学杂志,2015,95:1056- 1060.
• [28] Martínez López JA,García Vivar ML,Cáliz R,et al.Recomendaciones sobre actuaciones a seguir durante la edad fértil,el embarazo,posparto y lactancia en pacientes con enfermedades reumáticas inflamatorias y autoinmunes[J].Reumatología Clínica,2017,13:264- 281.
• [29] Sammaritano L,Bermas B,Chambers C,et al.2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.[J].Arthritis Care Res,2020,72:461- 488.
• [30] Cyprian F,Lefkou E,Varoudi K,et al.Immunomodulatory Effects of Vitamin D in Pregnancy and Beyond[J].Front Immunol,2019,10:2739.
• [31] Flint J,Panchal S,Hurrell A,et al.BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I:standard and biologic disease modifying anti-rheumatic drugs and corticosteroids[J].Rheumatology(Oxford),2016,55:1693- 1697.
• [32] Marder W.Update on pregnancy complications in systemic lupus erythematosus[J].Curr Opin Rheumatol,2019,31:650- 658.
• [33] G?testam Skorpen C,Hoeltzenbein M,Tincani A,et al.The EULAR points to consider for use of antirheumatic drugs before pregnancy,and during pregnancy and lactation[J].Ann Rheum Dis,2016,75:795- 810.
• [34] Liu X,Qiu Y,Yu ED,et al.Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome:A systematic review and network meta-analysis[J].Am J Reprod Immunol,2019,83:e13219.
• [35] Sciascia S,Hunt BJ,Talavera-Garcia E,et al.The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies[J].Am J Obstet Gynecol,2016,214:271- 273.
• [36] Mekinian A,Lazzaroni MG,Kuzenko A,et al.The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome:Data from a European multicenter retrospective study[J].Autoimmun Rev,2015,14:498- 502.
• [37] Bramham K,Thomas M,Nelson-Piercy C,et al.First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss[J].Blood,2011,117:6948- 6951.
• [38] Svenungsson E,Antovic A.The Antiphospholipid Syndrome-often overlooked cause of vascular occlusions?[J].J Intern Med,2020,287:349- 372.
• [39] Sammaritano LR,Bermas BL.Management of pregnancy and lactation[J].Best Pract Res Clin Rheumatol,2018,32:750- 766.
• [40] G?testam Skorpen C,Hoeltzenbein M,Tincani A,et al.The EULAR points to consider for use of antirheumatic drugs before pregnancy,and during pregnancy and lactation[J].Ann Rheum Dis,2016,75:795- 810.